CRC Research Update — October 22, 2026
Today's colorectal cancer research highlights
kras
A collection of 116 issues
CRC Research Update — October 20, 2026
Today's colorectal cancer research highlights
PIK3CA and BRAF mutations linked to worse outcomes in RAS wild-type mCRC on anti-EGFR therapy
Skip to content
The CRC Digest
PIK3CA and BRAF mutations linked to worse outcomes in RAS wild-type mCRC on anti-EGFR therapy
A meta-analysis of 1,478 RAS wild-type mCRC patients found PIK3CA mutations were associated with significantly worse PFS (HR 1.38) and OS (HR 1.58), while BRAF mutations
CRC Research Update — October 17, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 15, 2026
Today's colorectal cancer research highlights
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Skip to content
The CRC Digest
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Isogenic cell models revealed that RAS pathway mutations reconfigure chromatin accessibility and modulate WNT signaling, with elevated TCF7L2 expression in BRAF-mutant tumors independently predicting worse overall survival. (Cell Commun Signal)
This content is informational
CRC Research Update — October 14, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 10, 2026
Today's colorectal cancer research highlights
KRAS mutations in 63.54% of metastatic CRC patients
Skip to content
The CRC Digest
KRAS mutations in 63.54% of metastatic CRC patients
A retrospective study of 96 patients with metastatic colorectal cancer found KRAS mutations in 63.54% of patients, predominantly in codon 12 (70.49%) and codon 13 (14.75%). (Arq Bras Cir Dig)
This content